BDR Pharma launches patient-friendly prostrate cancer therapy
Tuesday, 2 January 2024 BDR Pharma launches BDENZA (Enzalutamide), the world's first oral solution for prostate cancer management. BDENZA is priced at Rs 27,000 for 150mL, offering reduced dosing frequency, toxicity, and side effects compared to existing oral formulations. The innovative formulation improves patient compliance with its palatable sugar-free taste and affordability. It also allows for dose adjustment based on consumption volume, addressing the challenges faced by patients. Prostate cancer is a growing concern, with an estimated 375,000 deaths, according to the WHO.
FDA Orders Drugmakers , to Add Cancer Warning to , CAR-T Treatments.
This week, the Food and Drug Administration
ordered drugmakers to add a warning to
CAR-T cancer therapy, saying that..
Credit: Wibbitz Top Stories Duration: 01:31Published
Tuesday, 2 January 2024
![FDA Orders Drugmakers to Add Cancer Warning to CAR-T Treatments [Video]](https://video.newsserve.net/300/v/20240124/1364181304-FDA-Orders-Drugmakers-to-Add-Cancer-Warning-to.jpg)
